ACS Med Chem Lett. 2019 Apr 29;10(5):694-695. doi: 10.1021/acsmedchemlett.9b00127. eCollection 2019 May 9.
Author information
Abstract
The nonpsychoactive phytocannabinoid, CBD, was recently approved by the Food and Drug Administration for the treatment of children with drug-resistant epilepsy. This milestone opens new avenues for cannabinoid research. In this Viewpoint, we provide an overview of recent progress in the field highlighting molecular insights into CBD’s mechanism of action, as well as its therapeutic potential.
- PMID: 31097982
- PMCID: PMC6511966
- [Available on 2020-05-09]
- DOI: 10.1021/acsmedchemlett.9b00127
Conflict of interest statement
The authors declare no competing financial interest.
